Install
Research shows gut microbiome could delay onset of type 1 diabetes Race opens first Australian clinical site for RC220 Phase 1 solid tumour trial Biome secures news debt facility to support growth Algorae announces the appointment of chief commercial officer Percheron updates shareholders after disappointing clinical t
- 30articles · 30d
- 2+ hour agolatest article
- Aug 17, 2026earliest in window
- 97%with images
- 336avg words
- Medical 23
- Health & Wellness 20
- Health 13
- Economy, Business & Finance 11
- Business & Industrial 6
- Science & Technology 5
- Finance & Business 4
- News 4
Please confirm you are human
This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.
A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.
News
Dimerix banks payment from Everest as global licensing strategy gathers pace
3+ week, 4+ day ago (551+ words) Dimerix has received a US$10 million upfront payment from Everest Medicines under its commercial licensing agreement for its lead kidney disease candidate, DMX-200, adding further financial weight to the Melbourne biotechnology company’s push towards a pivotal Phase 3 readout. The payment, worth…...
Medical Developments confirms building momentum as Penthrox sales grow
3+ week, 4+ day ago (655+ words) Medical Developments International reported higher profitability and stronger cash generation, with accelerating demand for Penthrox in Australia and Europe supporting a more positive outlook for the emergency pain relief specialist. The company reported net profit after tax of $0.6 million for…...
Recce advances pivotal diabetic foot infection trial with active antibiotic comparator arm
3+ week, 4+ day ago (340+ words) Recce Pharmaceuticals has secured Australian ethics approval to expand its pivotal Phase 3 trial of RECCE 327 Topical Gel by adding a head-to-head study against antibiotics currently used to treat diabetic foot infections. The Human Research Ethics Committee has approved an amendment…...
Dimerix takes control of US development pathway for new kidney injury treatment
3+ week, 6+ day ago (311+ words) Dimerix has taken over sponsorship of a United States investigational new drug application for DMX-652, giving the Australian biotechnology company direct control of clinical development plans for its newly acquired acute kidney injury asset. The Melbourne-based company said the transfer from…...